Erratum to: Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma. [EJC Skin Cancer, Volume 3, 2025, 100727] (EJC Skin Cancer (2025) 3, (S2772611825004483), (10.1016/j.ejcskn.2025.100727))

Emanuel Bührer; Nina Glassee; Michal Kicinski; Oliver J. Kennedy; Christian U. Blank; Georgina V. Long; Victoria G. Atkinson; Stéphane Dalle; Andrew M. Haydon; Andrey Meshcheryakov; Adnan Khattak; Matteo S. Carlino; Shahneen Sandhu; James Larkin; Susana Puig; Paolo A. Ascierto; Piotr Rutkowski; Dirk Schadendorf; Marye Boers-Sonderen; Anna Maria Di Giacomo; Alfonsus J.M. van den Eertwegh; Jean Jacques Grob; Ralf Gutzmer; Rahima Jamal; Alexander C.J. van Akkooi; Sara Gandini; Sara Valpione; Stefan Suciu; Caroline Robert; Alexander M.M. Eggermont; Paul Lorigan; Mario Mandala

doi:10.1016/j.ejcskn.2026.101132

Erratum to: Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma. [EJC Skin Cancer, Volume 3, 2025, 100727] (EJC Skin Cancer (2025) 3, (S2772611825004483), (10.1016/j.ejcskn.2025.100727))

Emanuel Bührer
, Nina Glassee
, Michal Kicinski
, Oliver J. Kennedy
, Christian U. Blank
, Georgina V. Long
, Victoria G. Atkinson
, Stéphane Dalle
, Andrew M. Haydon
, Andrey Meshcheryakov
, Adnan Khattak
, Matteo S. Carlino
, Shahneen Sandhu
, James Larkin
, Susana Puig
, Paolo A. Ascierto
, Piotr Rutkowski
, Dirk Schadendorf
, Marye Boers-Sonderen
, Anna Maria Di Giacomo

Alfonsus J.M. van den Eertwegh, Jean Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C.J. van Akkooi, Sara Gandini, Sara Valpione, Stefan Suciu, Caroline Robert, Alexander M.M. Eggermont, Paul Lorigan, Mario Mandala

Research related

Onderzoeksoutput: Bijdrage aan tijdschrift › Opmerking/debat

Samenvatting

The publisher regrets the omission of the editor is an author declaration: The author Dirk Schadendorf is an Editor of EJC Skin Cancer and were not involved in the editorial review or the decision to publish this article. The publisher would like to apologise for any inconvenience caused DOI of original article: https://doi.org/10.1016/j.ejcskn.2025.100727

Originele taal-2	Engels
Artikelnummer	101132
Tijdschrift	EJC Skin Cancer
DOI's	https://doi.org/10.1016/j.ejcskn.2026.101132
Status	Geaccepteerd/In druk - 2026

Toegang tot document

10.1016/j.ejcskn.2026.101132

Vingerafdruk

Duik in de onderzoeksthema's van 'Erratum to: Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma. [EJC Skin Cancer, Volume 3, 2025, 100727] (EJC Skin Cancer (2025) 3, (S2772611825004483), (10.1016/j.ejcskn.2025.100727))'. Samen vormen ze een unieke vingerafdruk.

Citeer dit

Bührer, E., Glassee, N., Kicinski, M., Kennedy, O. J., Blank, C. U., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A. M., Meshcheryakov, A., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Boers-Sonderen, M., ... Mandala, M. (Geaccepteerd/In druk). Erratum to: Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma. [EJC Skin Cancer, Volume 3, 2025, 100727] (EJC Skin Cancer (2025) 3, (S2772611825004483), (10.1016/j.ejcskn.2025.100727)). EJC Skin Cancer, Artikel 101132. https://doi.org/10.1016/j.ejcskn.2026.101132

Bührer, Emanuel ; Glassee, Nina ; Kicinski, Michal et al. / Erratum to : Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma. [EJC Skin Cancer, Volume 3, 2025, 100727] (EJC Skin Cancer (2025) 3, (S2772611825004483), (10.1016/j.ejcskn.2025.100727)). In: EJC Skin Cancer. 2026.

@article{210d1cb00feb4e3380051706c68b2b4f,

title = "Erratum to: Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma. [EJC Skin Cancer, Volume 3, 2025, 100727] (EJC Skin Cancer (2025) 3, (S2772611825004483), (10.1016/j.ejcskn.2025.100727))",

abstract = "The publisher regrets the omission of the editor is an author declaration: The author Dirk Schadendorf is an Editor of EJC Skin Cancer and were not involved in the editorial review or the decision to publish this article. The publisher would like to apologise for any inconvenience caused DOI of original article: https://doi.org/10.1016/j.ejcskn.2025.100727",

author = "Emanuel B{\"u}hrer and Nina Glassee and Michal Kicinski and Kennedy, \{Oliver J.\} and Blank, \{Christian U.\} and Long, \{Georgina V.\} and Atkinson, \{Victoria G.\} and St{\'e}phane Dalle and Haydon, \{Andrew M.\} and Andrey Meshcheryakov and Adnan Khattak and Carlino, \{Matteo S.\} and Shahneen Sandhu and James Larkin and Susana Puig and Ascierto, \{Paolo A.\} and Piotr Rutkowski and Dirk Schadendorf and Marye Boers-Sonderen and \{Di Giacomo\}, \{Anna Maria\} and \{van den Eertwegh\}, \{Alfonsus J.M.\} and Grob, \{Jean Jacques\} and Ralf Gutzmer and Rahima Jamal and \{van Akkooi\}, \{Alexander C.J.\} and Sara Gandini and Sara Valpione and Stefan Suciu and Caroline Robert and Eggermont, \{Alexander M.M.\} and Paul Lorigan and Mario Mandala",

note = "Publisher Copyright: {\textcopyright} 2026 The Authors",

year = "2026",

doi = "10.1016/j.ejcskn.2026.101132",

language = "English",

journal = "EJC Skin Cancer",

issn = "2772-6118",

publisher = "Elsevier BV",

}

Bührer, E, Glassee, N, Kicinski, M, Kennedy, OJ, Blank, CU, Long, GV, Atkinson, VG, Dalle, S, Haydon, AM, Meshcheryakov, A, Khattak, A, Carlino, MS, Sandhu, S, Larkin, J, Puig, S, Ascierto, PA, Rutkowski, P, Schadendorf, D, Boers-Sonderen, M, Di Giacomo, AM, van den Eertwegh, AJM, Grob, JJ, Gutzmer, R, Jamal, R, van Akkooi, ACJ, Gandini, S, Valpione, S, Suciu, S, Robert, C, Eggermont, AMM, Lorigan, P & Mandala, M 2026, 'Erratum to: Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma. [EJC Skin Cancer, Volume 3, 2025, 100727] (EJC Skin Cancer (2025) 3, (S2772611825004483), (10.1016/j.ejcskn.2025.100727))', EJC Skin Cancer. https://doi.org/10.1016/j.ejcskn.2026.101132

Erratum to: Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma. [EJC Skin Cancer, Volume 3, 2025, 100727] (EJC Skin Cancer (2025) 3, (S2772611825004483), (10.1016/j.ejcskn.2025.100727)). / Bührer, Emanuel; Glassee, Nina; Kicinski, Michal et al.
In: EJC Skin Cancer, 2026.

Onderzoeksoutput: Bijdrage aan tijdschrift › Opmerking/debat

TY - JOUR

T1 - Erratum to

T2 - Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma. [EJC Skin Cancer, Volume 3, 2025, 100727] (EJC Skin Cancer (2025) 3, (S2772611825004483), (10.1016/j.ejcskn.2025.100727))

AU - Bührer, Emanuel

AU - Glassee, Nina

AU - Kicinski, Michal

AU - Kennedy, Oliver J.

AU - Blank, Christian U.

AU - Long, Georgina V.

AU - Atkinson, Victoria G.

AU - Dalle, Stéphane

AU - Haydon, Andrew M.

AU - Meshcheryakov, Andrey

AU - Khattak, Adnan

AU - Carlino, Matteo S.

AU - Sandhu, Shahneen

AU - Larkin, James

AU - Puig, Susana

AU - Ascierto, Paolo A.

AU - Rutkowski, Piotr

AU - Schadendorf, Dirk

AU - Boers-Sonderen, Marye

AU - Di Giacomo, Anna Maria

AU - van den Eertwegh, Alfonsus J.M.

AU - Grob, Jean Jacques

AU - Gutzmer, Ralf

AU - Jamal, Rahima

AU - van Akkooi, Alexander C.J.

AU - Gandini, Sara

AU - Valpione, Sara

AU - Suciu, Stefan

AU - Robert, Caroline

AU - Eggermont, Alexander M.M.

AU - Lorigan, Paul

AU - Mandala, Mario

PY - 2026

Y1 - 2026

N2 - The publisher regrets the omission of the editor is an author declaration: The author Dirk Schadendorf is an Editor of EJC Skin Cancer and were not involved in the editorial review or the decision to publish this article. The publisher would like to apologise for any inconvenience caused DOI of original article: https://doi.org/10.1016/j.ejcskn.2025.100727

AB - The publisher regrets the omission of the editor is an author declaration: The author Dirk Schadendorf is an Editor of EJC Skin Cancer and were not involved in the editorial review or the decision to publish this article. The publisher would like to apologise for any inconvenience caused DOI of original article: https://doi.org/10.1016/j.ejcskn.2025.100727

UR - https://www.scopus.com/pages/publications/105034420960

U2 - 10.1016/j.ejcskn.2026.101132

DO - 10.1016/j.ejcskn.2026.101132

M3 - Comment/debate

AN - SCOPUS:105034420960

SN - 2772-6118

JO - EJC Skin Cancer

JF - EJC Skin Cancer

M1 - 101132

ER -

Bührer E, Glassee N, Kicinski M, Kennedy OJ, Blank CU, Long GV et al. Erratum to: Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma. [EJC Skin Cancer, Volume 3, 2025, 100727] (EJC Skin Cancer (2025) 3, (S2772611825004483), (10.1016/j.ejcskn.2025.100727)). EJC Skin Cancer. 2026;101132. doi: 10.1016/j.ejcskn.2026.101132